Letters to Policy Makers

Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.
2023 Federal Advocacy Letters
ACR Letter Addressing the High Prices of Drugs Covered under Medicare Part B – 5/5/2023
ACR Joins Letter to House Original Co-Sponsors of the Strengthening Medicare for Patients and Providers Act Thanking them for the Legislation Which Would Apply a Permanent Inflation-Based Update to the MPFS Conversion Factor – 5/3/2023ACR Comments on IRA Drug Price Negotiation Guidance – 4/14/2023
ACR Provides Comments on MACRA In Response to Congressional RFI – 10/31/2022
ACR Comments on the CY23 Medicare Physician Fee Schedule and Quality Payment Program – 9/6/2022
ACR Provides Comments to FTC Regarding Pharmacy Benefit Manager Business Practices – 5/23/2022
ACR Joins ATAP Sign-On Letter to FTC Regarding PBMs – 5/11/2022
ACR Congratulates New FDA Commissioner Robert Califf, MD, MACC – 2/18/2022
Finance Hearing Request Letter: Advancing Prior Authorization Legislation – 1/28/2022